A double-blind prospective randomized clinical trial of treatment for optic neuritis comparing visual outcome of patients treated by standard therapy (intravenous methylprednisolone) + placebo injection and standard therapy + retrobulbar methylprednisolone.

A double-blind prospective randomized clinical trial of treatment for optic neuritis comparing visual outcome of patients treated by standard therapy (intravenous methylprednisolone) + placebo injection and standard therapy + retrobulbar methylprednisolone.

Enrollment: 50. Randomized groups (2)

1. Standard treatment + placebo
2. Standard treatment + intervention Masking: Double (participant and outcomes assessor) Participants won't be aware to which group they were assigned. Investigator in charge of assessing outcomes and analyzing data won't be aware to which group participants were assigned

Inclusion Criteria:

• Both genres
• Age between 18 and 85 years old.
• Optic neuritis diagnosis ( relative afferent pupillary defect, acquired dyschromatopsia, low vision, prechiasmatic campimetric defect)
• 1 month after symptoms started
• If is a bilateral simultaneous optic neuritis the eye with the worst vision will be included.
• if is a bilateral sequential optic neuritis the eye with lees 1 month evolution will be included.

Exclusion Criteria:

• Visual field better than 20/60 at the beginning of the study.
• History of optic neuritis in the eye under study.
• History of additional ophthalmological or neurological pathology that has caused visual loss in the eye under study.
• History of previous treatment with intravenous methylprednisolone since the onset of symptoms.
• History of high myopia.

This study is confidential and no information will be shared with the participants.

Participants won't be aware to which group they were assigned. Investigator in charge of assessing outcomes and analyzing data won't be aware to which group participants were assigned.